Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 28, 2022 10:00 ET | Source: HIV Prevention Trials Network (HPTN)

Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women - Findings from HPTN 084 Study

DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) -- Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure...
December 21, 2021 14:42 ET | Source: HIV Prevention Trials Network (HPTN)

HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention

DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important information for yesterday’s decision by the...
June 09, 2021 10:20 ET | Source: HIV Prevention Trials Network (HPTN)

HIV Prevention Trials Network Launches HPTN 094 (INTEGRA) Study

Durham, N.C., June 09, 2021 (GLOBE NEWSWIRE) -- The HIV Prevention Trials Network (HPTN) announced today the launch of HPTN 094 (INTEGRA), a study to determine whether using mobile health units to...
November 30, 2020 22:32 ET | Source: HIV Prevention Trials Network (HPTN)

HIV Prevention Trials Network Awarded U.S. National Institutes of Health Funding to Continue Research Agenda

DURHAM, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Drs. Myron S. Cohen and Wafaa M. El-Sadr, principal investigators of the HIV Prevention Trials Network (HPTN), in collaboration with FHI 360, have...
May 18, 2020 06:37 ET | Source: HIV Prevention Trials Network (HPTN)

Long-Acting Injectable Cabotegravir Is Highly Effective for the Prevention of HIV Infection in Cisgender Men and Transgender Women Who Have Sex With Men

DURHAM, N.C., May 18, 2020 (GLOBE NEWSWIRE) -- The HIV Prevention Trials Network (HPTN) announced today results from HPTN 083, a global randomized, controlled, double-blind study that compared the...